Nuage Therapeutics engages in developing drugs which target proteins in disordered regions for challenging indications faced by patients.
Nuage Therapeutics has raised $12.9M in total funding. The most recent round was Seed. The last funding was announced in March 2023.
Nuage Therapeutics's investors include Sofinnova Partners, Asabys Partners, Centre for the Development of Industrial Technology (CDTI), BStartup - Banc Sabadell.
Nuage Therapeutics is headquartered in Barcelona, Spain.
Nuage Therapeutics engages in developing drugs which target proteins in disordered regions for challenging indications faced by patients.
Nuage Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nuage Therapeutics — Funding & Investors." VCBacked, March 14, 2023, https://www.vcbacked.co/company/nuage-therapeutics. Accessed August 17, 2026.
VCBacked. (2023). Nuage Therapeutics — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/nuage-therapeutics
{{cite web |title=Nuage Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nuage-therapeutics |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated